Moderna Briefly Loses Top Spot on S&P 500 After Vaccine View
(Bloomberg) -- Moderna Inc. plunged Thursday, briefly losing its place as the best performing stock on the S&P 500 Index.
The biotech's stock closed down 18%, the biggest daily drop since March 2020, after a weakened outlook for its Covid-19 vaccine and sales that missed the average analyst estimate. For a few minutes the vaccine maker was supplanted by shale oil producer Devon Energy Corp., before finishing the day back in the lead.
The U.K.'s approval of Merck & Co.'s Covid-19 antiviral pill also hit Moderna's shares. British regulators described the treatment as safe and effective and more authorizations could hurt the sales of Covid vaccines.
The drugmaker's meteoric rally earlier this year led to its addition into the benchmark S&P 500 in July after its coronavirus inoculation received emergency authorization in the U.S. in December, a week behind the first approval for Pfizer Inc. and BioNTech SE's vaccine. But concerns about the future sales have weighed on the shares. Moderna has slumped more than 40% since a peak in August.
“Shares remain substantially overvalued,” wrote SVB Leerink analyst Mani Foroohar in a research note. The market for Covid vaccines is transitioning to “a much smaller, much more competitive chronic endemic market,” he added.
Ten analysts covering Moderna have either a hold or sell recommendation with only seven suggesting investors buy the stock, data compiled by Bloomberg show. Its shares are still up roughly 172% this year.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.